EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Somatostatin receptor 2A expression in von Hippel‐Lindau–related hemangioblastomas

Saya Ahmad, Angelika Muhlebner, Tom J Snijders, Wendy W de Leng, Tatjana Seute, Rachel S van Leeuwaarde iD

Cancer · 2024

DOI: 10.1002/cncr.35418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Saya Ahmad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Hemangioblastoma, von Hippel-Lindau Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Central nervous system hemangioblastomas are the most prevalent manifestation of von Hippel‐Lindau (VHL) disease and remain the main cause of mortality. Surgical resection is the primary treatment strategy, but is not always possible, and should be used as restrictively as possible. There is an unmet need for less invasive treatment strategies, such as targeted therapy. Expression of somatostatin receptor 2A (SSTR2A) in VHL‐related hemangioblastomas has been described earlier, but the extent of expression in a larger population has yet to be determined. The authors hypothesize that a substantial subset of VHL‐related hemangioblastomas show SSTR2A expression, which may serve as a potential new treatment target.

Methods

Patients who were surgically treated for a VHL‐related hemangioblastoma from 1990 until 2021 at the UMC Utrecht were included. Clinical data was derived from a clinical database. Tissue samples were histopathologically examined with use of hematoxylin and eosin staining, and immunohistochemical analysis of SSTR2A expression was performed.

Results

Forty‐three tissue samples were obtained from 26 patients. Nine showed strong positivity for SSTR2A expression, whereas 13 showed moderate and 15 sparse expression. Three samples showed no expression of SSTR2A. The distribution showed right‐skewedness favoring a strong expression. SSTR2A expression colocalized with endothelial markers and not with stromal cells. Additionally, within‐patient variability for SSTR2A expression was described in 14 patients.

Conclusion

SSTR2A is expressed in varying degrees in the majority of VHL‐related hemangioblastomas. Future treatment with somatostatin analogues or even peptide receptor radionuclide treatment may be considered for SSTR2A‐positive cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, SomatostatinHemangioblastomavon Hippel-Lindau DiseaseHumansFemaleAdultMaleMiddle AgedAgedCerebellar NeoplasmsYoung AdultImmunohistochemistry

Stichwörter der Autor:innen

hemangioblastomassomatostatinsomatostatin expressionvon Hippel‐Lindau

Substanzen

Receptors, Somatostatinsomatostatin receptor 2

Autor:innen und Institutionen

  • Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID-Profile: Rachel S van Leeuwaarde

Zitieren

APA

Ahmad, S., Muhlebner, A., Snijders, T. J., de Leng, W. W., Seute, T., & van Leeuwaarde, R. S. (2024). Somatostatin receptor 2A expression in von Hippel‐Lindau–related hemangioblastomas. Cancer. https://doi.org/10.1002/cncr.35418

Vancouver

Ahmad S, Muhlebner A, Snijders TJ, de Leng WW, Seute T, van Leeuwaarde RS. Somatostatin receptor 2A expression in von Hippel‐Lindau–related hemangioblastomas. Cancer. 2024. doi:10.1002/cncr.35418

BibTeX
@article{Ahmad2024,
  author = {Ahmad, Saya and Muhlebner, Angelika and Snijders, Tom J and de Leng, Wendy W and Seute, Tatjana and van Leeuwaarde, Rachel S},
  title = {Somatostatin receptor 2A expression in von Hippel‐Lindau–related hemangioblastomas},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35418}
}
Kostenlos starten →